– USA, MA – Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced the appointment of Barry Greene as CEO.
Mr. Greene, who most recently served as president of Alnylam Pharmaceuticals, Inc., from 2007 to September 2020, and as COO from 2003 to 2016, will also continue as a member of Sage’s board of directors.
“I’ve known and worked with Barry for 20 years,” said Board Chairman, Kevin Starr. “His appointment as CEO is the result of thoughtful succession discussions with the Board, with the aim of augmenting the executive bench with a world-class leader committed to moving Sage to the next stage of growth and commercialization. Barry is ideal to lead this mission: he has a significant track record of successfully executing on R&D and commercialization strategies. He has built and grown a multiproduct company and is very familiar with Sage’s business and culture. Having Barry as CEO and Jeff as CInO strengthens Sage for its next evolution.”
Dr. Jonas will continue to advance the Company’s mission in the new role of chief innovation officer. In this capacity, he will bring his thought leadership and the creative, innovative thinking for which Sage is known. He will remain a member of the board and will chair Sage’s Science & Technology Forum of the Board. As chief innovation officer, Jeff will focus on his well-recognized expertise — neuroscience, development, and pipeline expansion — bringing to bear in the role his creative thinking and extensive drug development experience.
“I am optimistic about what we have done to advance breakthrough science with the goal of delivering truly different approaches to treat brain health disorders. We always had the vision of upending the conventional wisdom of how to think about and how to treat these disorders,” said Dr. Jeff Jonas, chief innovation officer and formerly CEO. “I am proud of the progress we have made on this journey — we took the company from a research organization to a fully integrated biopharmaceutical company with the first approved product for postpartum depression and one of the strongest brain health pipelines in the industry. Our ability to attract Barry’s caliber of talent as our next CEO is a testament to these efforts and he’s committed to continuing to make progress on our journey to provide groundbreaking options for people with brain health disorders. I look forward to working with Barry and the Sage team moving forward and continuing to contribute to Sage’s advancement in my new role.”
About Barry Greene
Barry Greene joined the Sage Board of Directors in October 2020 bringing more than 30 years of experience to this position. Prior to Sage, he served as president of Alnylam Pharmaceuticals, Inc., since 2007 and he previously held the position of chief operating officer when he first joined the company in 2003. Prior to his 17 year tenure at Alnylam, Mr. Greene was the general manager of Oncology at Millennium Pharmaceuticals, Inc. where he led the Company’s global strategy and execution for its oncology business, including strategic business direction and execution, culminating in the successful U.S. Food and Drug Administration approval and launch of VELCADE in mid-2003. Prior to joining Millennium in 2001, Mr. Greene served as executive vice president and chief business officer for Mediconsult.com, a healthcare consulting company. Earlier in Mr. Greene’s career, he held multiple leadership positions at AstraZeneca, and was a partner of Andersen Consulting, where he was responsible for the pharmaceutical/biotechnology marketing and sales practice.
“Sage is taking on one of the biggest challenges we face today with the urgent and escalating need for more options to transform the lives of millions of patients with debilitating brain health disorders,” said CEO. Barry Greene. “I am impressed by the groundbreaking and relentless pursuit that Jeff has spearheaded, and one that the entire organization has embraced, to bring a new way of thinking about how we can treat brain health disorders differently. Together, Jeff with his unique neuroscience expertise, and I, along with the talented team at Sage, can leverage our collective strengths in our efforts to bring new options to patients in areas that have been lacking innovation for a very long time. I look forward to being part of such a passionate and committed team as we advance Sage’s multi-franchise strategy and work to deliver on our mission to bring positive impact to the lives of many patients and their families.”
He received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University’s Fuqua School of Business.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
For more information : https://www.sagerx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
